BRITISH COLUMBIA CANCER AGENCY BRANCH Patent applications |
Patent application number | Title | Published |
20150377787 | INTEGRATED SPECTRAL PROBE FOR RAMAN, REFLECTANCE AND FLUORESCENCE SPECTRAL MEASUREMENTS - Examples of a spectroscopy probe for performing measurements of Raman spectra, reflectance spectra and fluorescence spectra are disclosed. The integrated spectral probe can comprise one or more light sources to provide a white light illumination to generate reflectance spectra, an excitation light to generate an UV/visible fluorescence spectra and a narrow band NIR excitation to induce Raman spectra. The multiple modalities of spectral measurements can be performed within 2 seconds or less. Examples of methods of operating the integrated spectroscopy probe disclosed. | 12-31-2015 |
20150132297 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients. | 05-14-2015 |
20150125389 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 05-07-2015 |
20150010469 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 01-08-2015 |
20140342920 | Biomarkers for Non-Hodkin Lymphomas and Uses Thereof - The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods of classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the same for a mutation in one or more biomarkers. | 11-20-2014 |
20140335080 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE - Compounds having a structure of Structure I: | 11-13-2014 |
20140309636 | INTRAMEDULLARY FIXATION SYSTEM FOR MANAGEMENT OF PELVIC AND ACETABULAR FRACTURES - Devices for treating a bone and methods of inserting such devices into a bone are disclosed. A device for treating a bone may include a flexible tube, a stiffening mechanism and an actuator. The flexible tube has a distal end and a proximal end. The stiffening mechanism within the flexible tube is configured to cause the flexible tube to become rigid. The actuator is configured to cause the stiffening mechanism to cause the flexible tube to become rigid in response to the actuator being actuated. | 10-16-2014 |
20140248263 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: wherein G, a, Q, L | 09-04-2014 |
20140236022 | SCANNING OPTICAL SYSTEMS - Scanning mechanisms that have application in confocal imaging use electromagnetic actuation to move elements in an optical system. An objective lens mounted to a flexure comprising a magnetic material is actuated in the axial direction by an electromagnet coil. An optical path may pass through the coil. Scanning in transverse directions may be provided using magnetically actuated flexible beams which move the tip of an optical fiber or other pinhole in one or more transverse directions. Actuators may be actuated using driving currents that include an AC component and a DC bias component. The scanning mechanisms may be miniaturized and may be constructed to provide real-time imaging. | 08-21-2014 |
20140202859 | AUTOMATED SIZE SELECTION OF NUCLEIC ACIDS - Apparatus and methods for size selecting nucleic acid molecules having wide range of applications including the production of DNA libraries for sequencing technologies. An automated high throughput system for size selection of multiple nucleic acid samples that uses imaging technique to detect the progress of a target fraction and feedback from the imaging to control electrophoresis. Predictive algorithms for timed nucleic acid extractions are generated to provide size selected nucleic acid molecules of required size ranges. | 07-24-2014 |
20140066862 | ERGONOMIC SYRINGE SYSTEMS - Ergonomic syringe systems provide attachments that may be used to allow users to dispense or draw in fluid with increased operator comfort and reduced risk of repetitive strain injuries. The disclosure describes supports for holding syringes that permit one-handed operation, handles that are removably attachable to syringe plungers and hand supports that are removably attachable to syringe barrels. | 03-06-2014 |
20140023993 | APPARATUS AND METHODS FOR MULTIPHOTON MICROSCOPY - A multiphoton microscope is provided. The microscope includes: an excitation source for providing an optical excitation beam at an excitation wavelength λ; a scanner for scanning the excitation beam on a sample; an objective for irradiating the sample with the excitation beam scanned by the scanner and for collecting an emission beam from the sample; a first detector for detecting a plurality of multiphoton signals; and an emission light path allowing transmission from the objective to the first detector a wavelength band limited to greater than or equal to λ/2 and less than λ, wherein the plurality of multiphoton signals have wavelengths within the wavelength band; wherein the plurality of multiphoton signals comprises a first multiphoton signal and a second multiphoton signal of different types. Fast image capture rate multiphoton microscopes for in vivo imaging, as well as photothermolysis methods using the microscopes are also provided. | 01-23-2014 |
20130336962 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 12-19-2013 |
20130245129 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE - This invention provides compound having a structure of Formula I or Formula II | 09-19-2013 |
20130231573 | APPARATUS AND METHODS FOR CHARACTERIZATION OF LUNG TISSUE BY RAMAN SPECTROSCOPY - Near-infrared Raman spectroscopy can be applied to identify preneoplastic lesions of the bronchial tree. Real-time in vivo Raman spectra of lung tissues may be obtained with a fiber optic catheter passed down the instrument channel of a bronchoscope. Using prototype apparatus, preneoplastic lesions were detected with sensitivity and specificity of 96 and 91% respectively. The use of Raman spectroscopy apparatus and methods in conjunction with other bronchoscopy imaging modalities can substantially reduce the number of false positive results. | 09-05-2013 |
20130209402 | HUMAN PAPILLOMAVIRUS E7 ANTIGEN COMPOSITIONS AND USES THEREOF - The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same. | 08-15-2013 |
20130197056 | NOVEL BIOMARKERS AND TARGETS FOR OVARIAN CARCINOMA - Novel biomarkers and targets associated with ovarian cancer, particularly clear-cell carcinoma, endometrioid carcinoma, and uterine carcinoma, are disclosed. Mutations in genes encoding proteins that form part of the SWI/SNF chromatin remodelling protein complex, including ARID1A, or loss of expression of such proteins, including BAF250a, can be used to evaluate the likelihood endometriosis will progress or transform to cancer, to provide a prognosis for a patient with cancer, to assess whether conventional treatment is likely to be effective against a cancer, and/or in a synthetic lethal screen to identify novel targets and therapeutics for the treatment of cancer. | 08-01-2013 |
20130195843 | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof - The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers. | 08-01-2013 |
20130131488 | MULTIMODAL DETECTION OF TISSUE ABNORMALITIES BASED ON RAMAN AND BACKGROUND FLUORESCENCE SPECTROSCOPY - Methods and apparatus for classifying tissue use features of Raman spectra and background fluorescent spectra. The spectra may be acquired in the near-infrared wavelengths. Principal component analysis and linear discriminant analysis of reference spectra may be used to obtain a classification function that accepts features of the Raman and background fluorescence spectra for test tissue and yields an indication as to the likelihood that the test tissue is abnormal. The methods and apparatus may be applied to screening for skin cancers or other diseases. | 05-23-2013 |
20130131167 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS - This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss. | 05-23-2013 |
20130065789 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 03-14-2013 |
20130045204 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 02-21-2013 |
20120301891 | BIOMARKERS OF CANCER METASTASIS - There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer. | 11-29-2012 |
20120259229 | APPARATUS AND METHODS FOR IN VIVO TISSUE CHARACTERIZATION BY RAMAN SPECTROSCOPY - A micro-Raman spectrometer system for use in differentiating tumor lesions from normal skin detects specific characteristics of Raman spectra indicative of cancer. A peak at 899 cm | 10-11-2012 |
20120225793 | METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS - Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject. | 09-06-2012 |
20120141603 | METHODS AND COMPOSITIONS FOR LUNG CANCER PROGNOSIS - Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy. | 06-07-2012 |
20120123184 | SYSTEMS AND METHODS FOR OPTIMIZATION OF ON-LINE ADAPTIVE RADIATION THERAPY - Radiation treatment methods comprise: obtaining initial image data of a region of interest; initially optimizing one or more radiation delivery variables of a radiation treatment plan based on the initial image data; and dividing the plan into one or more fractional treatments. Each fractional treatment comprises: delivering an initial portion of a fraction based on the one or more initially optimized radiation delivery variables; obtaining fractional image data pertaining to the region of interest; fractionally optimizing the one or more radiation delivery variables based at least in part on the fractional image data; and delivering a subsequent portion of the fraction based on the one or more fractionally optimized radiation delivery variables. At least part of delivering the initial portion of the fraction overlaps temporally with at least one of: obtaining the fractional image data and fractionally optimizing the one or more radiation delivery variables. | 05-17-2012 |
20120089030 | SYSTEM AND METHOD FOR CHARACTERIZATION OF ORAL, SYSTEMIC AND MUCOSAL TISSUE UTILIZING RAMAN SPECTROSCOPY - A method and system for characterizing tissue includes a probe connected to a red LASER source and a Raman spectroscope. The probe includes at least excitation fiber and one or more emission fibers that connect the probe with the LASER source and the Raman spectroscope. The excitation fiber is connected to the red LASER source and terminates in the first end of the probe adjacent the tip of the probe. The emission fibers are connected to the Raman spectroscope and terminate in the first end of the probe adjacent the tip of the probe. In one embodiment, the excitation fiber extends through the central portion of the probe and one or more emission fibers are arranged around the excitation fiber. The tip of the probe is intended to come in contact with the tissue to be examined. The tip includes a central opening to allow red LASER radiation to project out of the end of the red excitation fiber on to the tissue and to permit Raman spectra to enter the emission fiber(s) and travel to the Raman spectroscope. The tip is constructed to have a predefined focal length to position the first end of the probe a predefined distance from the surface of the tissue being examined. The tip can be removable and tips having different focal lengths can be used to accommodate different types of tissues and examinations. A detector can convert the Raman spectra into signals and data for analysis by a computer system. The Raman spectra for tissue in a predefined location can be profiled such that the system can distinguish between healthy and diseased tissue. | 04-12-2012 |
20120061590 | SELECTIVE EXCITATION LIGHT FLUORESCENCE IMAGING METHODS AND APPARATUS - Imaging methods and apparatus may be applied to image tissues as well as other areas. A computer-controlled color-selectable light source is controlled to emit light having a desired spectral profile and to illuminate an area. An imaging detector images the illuminated area. The spectral profile may be selected to yield images in which contrast between features of interest and other features is enhanced. The images may be combined into a composite image. In some embodiments the spectral profile is based on a principal components analysis such that the images each correspond to one principal component. | 03-15-2012 |
20120059346 | VIAL HANDLING AND INJECTION SAFETY SYSTEMS AND CONNECTORS - Systems and devices are provided to facilitate safe handling and injection of medicaments contained in vials. A vial handling system has at least one vial gripping member to hold a vial, and a filler pin movable relative to the vial gripping member for piercing a membrane seal on the vial. At least one window is provided in the vial handling system to permit access to remove a cap on the vial, while preventing needle access to the membrane seal through the window. In some embodiments, the vial contents are removed through a male end connector portion of a unique connector pair. A female end connector portion has a female socket with an inner fluid tube in fluid communication with a body of a syringe, while the male end connector portion has an engaging end dimensioned to fit within the female socket and securely overlap the inner fluid tube. | 03-08-2012 |
20120027793 | COMPOSITIONS COMPRISING CHLAMYDIA ANTIGENS - There is provided a composition for inducing an immune response to a | 02-02-2012 |
20110244024 | MICRORNA COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA - The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233. | 10-06-2011 |
20110224313 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 09-15-2011 |
20110195070 | DETECTION OF GRANULOSA-CELL TUMORS - A method of detecting a granulosa-cell tumor is described herein. The method involves detecting a mutation in a sample derived from a subject, indicative of substitution of tryptophan in place of cysteine at amino acid position 134 of FOXL2 protein. The mutation may be detected as a DNA mutation 402C>G in the FOXL2 gene. Methods for screening for a granulosa-cell tumor from a blood-based assay are provided, as well as methods for making a determination that an ovarian tumor is not a granulosa-cell tumor. Kits for granulosa-cell tumors are described, and a method of treating a granulosa-cell tumor are also described. | 08-11-2011 |
20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 08-11-2011 |
20110009369 | ANTI-INFLUENZA COMPOUNDS - The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds of the invention can also be used for the treatment or prophylaxis of a disease caused by | 01-13-2011 |
20100317533 | BIOMARKERS OF CANCER METASTASIS - There is provided a panel of biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), or tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. There is also provided a method of determining risk of tumour metastasis using the aforementioned biomarkers is also provided. The biomarkers may be used in diagnosis, prognosis, treatment selection, or to test putative therapeutics. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer. | 12-16-2010 |
20100290692 | SYSTEMS AND METHODS FOR AUTOMATED CHARACTERIZATION OF GENETIC HETEROGENEITY IN TISSUE SAMPLES - Systems and methods for the quantitative automated analysis of pathology samples identify groups of spatially-associated similar cells. Cells may be identified as belonging to a group on the basis of spatial location and biomarkers. In some embodiments the biomarkers are multicolour fluorescence in situ hybridization (FISH) signals. Characteristics of the cells in a group may be combined to provide quantitative FISH results that may compensate for variations and artefacts such as thin sectioning that can result in the loss of information due to damage. In heterogeneous tissue samples, grouping cells can permit quantitative results regarding pathological cells to be extracted despite the presences of infiltrating non pathological cells. | 11-18-2010 |
20100248290 | METHODS FOR DETECTING LUNG CANCER AND MONITORING TREATMENT RESPONSE - A method is described for detecting lung cancer comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject at risk for developing lung cancer. Further, a method is described for predicting risk of developing lung cancer in a subject comprising detecting an elevated level of a CTAP III-related biomarker in a biological sample from a subject. Additionally, a method of monitoring the success of lung cancer treatment with curative intent is described comprising detecting levels of a CTAP III-related biomarker in a biological sample from a subject undergoing treatment for lung cancer for comparison with the a previous level obtained from the subject. Multivariate analysis may be incorporated into these methods, evaluating such clinical, or demographic risk factors as age, sex, smoking history, smoking status, smoking family history, education level, COPD, socio-economic status, body mass index and lung function. Kits for conducting such methods are described. | 09-30-2010 |
20090035318 | METHOD AND COMPOSITION FOR INCREASING THE ENGRAFTMENT EFFICIENCY OF STEM CELLS - A method is described for increasing the engraftment efficiency of S/G | 02-05-2009 |
20090011456 | Methods for the Diagnosis and Prognosis of Graft Versus Host Disease By Measurement of Peripheral Cd3+Cd4+Cd8Beta+ Cells - Acute graft versus host disease (GvHD) is one of the most significant clinical problems in allogeneic blood and marrow transplantation. Currently, there is no unequivocal diagnostic test for GvHD until the disease is well developed and can be recognized histologically. The invention provides a blood based test for diagnosis and/or prognosis of GvHD, allowing assessment of risk for developing GvHD prior to appearance of clinical symptoms. Using flow cytometry, peripheral blood mononuclear cells are assessed for an increase in proportion and fluctuation of CD3 | 01-08-2009 |